Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Past Earnings Performance
Past criteria checks 1/6
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has been growing earnings at an average annual rate of 39.6%, while the Pharmaceuticals industry saw earnings growing at 11.3% annually. Revenues have been growing at an average rate of 32.6% per year. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi's return on equity is 9.3%, and it has net margins of 5.6%.
Key information
39.6%
Earnings growth rate
4.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 32.6% |
| Return on equity | 9.3% |
| Net Margin | 5.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 8,152 | 455 | 998 | 0 |
| 30 Sep 23 | 5,577 | 1,004 | 667 | 0 |
| 30 Jun 23 | 4,544 | 933 | 581 | 0 |
| 31 Mar 23 | 5,156 | 1,017 | 511 | 0 |
| 31 Dec 22 | 10,639 | 640 | 893 | 0 |
| 30 Sep 22 | 4,779 | 775 | 338 | 0 |
| 30 Jun 22 | 3,908 | 594 | 266 | 0 |
| 31 Mar 22 | 2,927 | 396 | 210 | 0 |
| 31 Dec 21 | 2,501 | 311 | 169 | 0 |
| 30 Sep 21 | 2,796 | 294 | 148 | 0 |
| 30 Jun 21 | 2,983 | 273 | 135 | 0 |
| 31 Mar 21 | 2,523 | 267 | 118 | 0 |
| 31 Dec 20 | 2,150 | 208 | 108 | 0 |
| 31 Dec 19 | 1,795 | 142 | 106 | 0 |
| 31 Dec 18 | 1,180 | 5 | 86 | 2 |
Quality Earnings: GENIL has a high level of non-cash earnings.
Growing Profit Margin: GENIL's current net profit margins (5.6%) are lower than last year (6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GENIL's earnings have grown significantly by 39.6% per year over the past 5 years.
Accelerating Growth: GENIL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GENIL had negative earnings growth (-29%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (5.8%).
Return on Equity
High ROE: GENIL's Return on Equity (9.3%) is considered low.